Elevated CXCR1 correlated with poorer tumor differentiation and reduced sensitivity to standard chemotherapy regimens (FOLFOX/XELOX), indicating that chemokine pathways may contribute to therapy resistance in this subgroup [127]. Here, CXCR1 is linked to neoplasm.